New Kind Of 'Designer' Immune Cells Clear Baby's Leukemia

Layla
Baby Layla (L) is seen with her parents, Lisa and Ashleigh, and her older sister Reya at Great Ormond Street Hospital (GOSH) in London in this November 4, 2015 handout photo by the hospital released on November 5, 2015.  REUTERS/Great Ormond Street Hospital/Handout via Reuters.

A baby whom doctors thought almost certain to die has been cleared of a previously incurable leukemia in the first human use of an "off-the-shelf" cell therapy from Cellectis that creates designer immune cells.

One-year-old Layla had run out of all other treatment options when doctors at Britain's Great Ormond Street Hospital (GOSH) gave her the highly experimental, genetically edited cells in a tiny 1-milliliter intravenous infusion.

Two months later, she was cancer-free and she is now home from hospital, the doctors said at a briefing about her case in London on Wednesday.

"Her leukemia was so aggressive that such a response is almost a miracle," said Paul Veys, a professor and director of bone marrow transplant at GOSH who led the team treating Layla.

"As this was the first time that the treatment had been used, we didn't know if or when it would work, so we were over the moon when it did."

The gene-edited cell treatment was prepared by scientists at GOSH and University College London (UCL) together with the French biotech firm Cellectis, which is now funding full clinical trials of the therapy due to start next year.

It is designed to work by adding new genes to healthy donated immune cells known as T-cells, which arm them against leukemia.

Using a gene-editing technology called TALEN, which acts as "molecular scissors," specific genes are then cut to make the T-cells behave in two specific ways: Firstly, they are rendered invisible to a powerful leukaemia drug that would usually kill them and secondly they are reprogrammed to only target and fight against leukemia cells.

Other drugmakers including Novartis, Juno Therapeutics and Kite Pharma have tested genetically modified T-cells extracted from an individual patient. However, this is the first time cells from a healthy donor have been used in a process could lead to a ready off-the-shelf supply for use in multiple patients.

Some scientists have questioned Cellectis' approach because of potential problems with patients rejecting foreign cells.

But the French biotech, working with the U.S. giant Pfizer, as well as Novartis believes its method is faster and cheaper than creating single patient-specific gene therapies.

Results from Layla's case were due to be presented at the American Society of Hematology's annual meeting in Orlando on Wednesday.

"This is a landmark in the use of new gene engineering technology and the effects for this child have been staggering," said Waseem Qasim, a professor of Cell and Gene Therapy at UCL and immunologist at GOSH who worked on her medical team.

If the success in this case is sustained and replicated in other patients, he said, the therapy "could represent a huge step forward in treating leukaemia and other cancers."

Matt Kaiser, head of research at the leukemia and lymphoma charity Bloodwise, said that while the concept of editing immune cells to recognize and hunt out leukemia cells is "very exciting," patients and their families should note that the technique is still in the very early stages of development.

"We need to establish whether it can offer a long-term cure, whether there are any side effects and which patients are most likely to benefit from it," he said.

    Most Popular
  • Is 'The Last Supper' worth watching? Audience and critics weigh in

    Is 'The Last Supper' worth watching? Audience and critics weigh in

    Faith-based films often receive mixed reactions, and The Last Supper is no exception. The movie attempts to bring a fresh perspective to one of the most iconic moments in Christian history, but does it succeed? Some reviews from critics and audiences provide insight into its strengths and shortcomings.

  • ‘The Chosen’ Season 5: The darkest season yet—What to know before watching

    The wait is over—The Chosen is back with its fifth season, and this time, things are getting intense. The new episodes dive straight into the final days of Jesus’ life, covering some of the most emotional and dramatic moments in the Bible. If you’ve been following the series, you already know that The Chosen isn’t just about retelling familiar stories—it’s about bringing them to life in a way that feels real.

  • Massacres in Syria: Over 1,000 dead, including Christians and Alawites

    Syria’s coastal regions have been devastated by a series of massacres, with reports indicating that over 1,000 people—many from Christian and Alawite communities—have been killed in brutal attacks. Entire families have been wiped out, and survivors are fleeing in search of safety as sectarian violence escalates.

  • Kim Sae-ron and Wheesung: The tragic irony of Korean society and the principles of happiness

    Not long ago, the media was in an uproar over actress Kim Sae-ron’s passing. Just months before, the same people who had relentlessly criticized her for her DUI incident were now expressing sympathy, saying, "The world was too harsh on her." The irony is impossible to ignore.

  • Newsboys move forward as a quartet after Michael Tait’s departure

    After more than a decade as the lead singer of the Newsboys, Michael Tait has officially parted ways with the band, marking a significant shift in the Christian rock group’s lineup. The remaining members—Jeff Frankenstein, Jody Davis, Duncan Phillips, and Adam Agee—have assured fans that they will continue forward, embracing a new season of music and ministry.